These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 6122057)
1. Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients. Hann IM; Prentice HG; Corringham R; Blacklock HA; Keaney M; Shannon M; Noone P; Gascoigne E; Fox J; Boesen E; Szawatkowski M; Hoffbrand AV Lancet; 1982 Apr; 1(8276):826-9. PubMed ID: 6122057 [TBL] [Abstract][Full Text] [Related]
2. Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. Boogaerts M; Maertens J; van Hoof A; de Bock R; Fillet G; Peetermans M; Selleslag D; Vandercam B; Vandewoude K; Zachée P; De Beule K J Antimicrob Chemother; 2001 Jul; 48(1):97-103. PubMed ID: 11418517 [TBL] [Abstract][Full Text] [Related]
3. Ketoconazole versus nystatin as prophylaxis against fungal infection for lymphoma patients receiving chemotherapy. Turhan A; Connors JM; Klimo P Am J Clin Oncol; 1987 Aug; 10(4):355-9. PubMed ID: 2441593 [TBL] [Abstract][Full Text] [Related]
4. Treatment of mycoses in cancer patients. Meunier-Carpentier F Am J Med; 1983 Jan; 74(1B):74-9. PubMed ID: 6295156 [TBL] [Abstract][Full Text] [Related]
5. Use of antifungal therapy in hospitalized patients. I. Results prior to the marketing of fluconazole. Grasela TH; Goodwin SD; Pasko MT; Walawander CA; Raebel MA Ann Pharmacother; 1994 Feb; 28(2):252-60. PubMed ID: 8173147 [TBL] [Abstract][Full Text] [Related]
6. Nystatin prophylaxis and treatment in severely immunodepressed patients. Gøtzsche PC; Johansen HK Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD002033. PubMed ID: 25188770 [TBL] [Abstract][Full Text] [Related]
7. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group. Philpott-Howard JN; Wade JJ; Mufti GJ; Brammer KW; Ehninger G J Antimicrob Chemother; 1993 Jun; 31(6):973-84. PubMed ID: 8360134 [TBL] [Abstract][Full Text] [Related]
8. Symposium on infectious complications of neoplastic disease (Part II). Chemoprophylaxis of fungal infections. Meunier-Carpentier F Am J Med; 1984 Apr; 76(4):652-6. PubMed ID: 6324589 [TBL] [Abstract][Full Text] [Related]
9. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group. Wolff SN; Fay J; Stevens D; Herzig RH; Pohlman B; Bolwell B; Lynch J; Ericson S; Freytes CO; LeMaistre F; Collins R; Pineiro L; Greer J; Stein R; Goodman SA; Dummer S Bone Marrow Transplant; 2000 Apr; 25(8):853-9. PubMed ID: 10808206 [TBL] [Abstract][Full Text] [Related]
10. Prophylaxis of mycotic infections in immunocompromised patients: a review of 27 reports and publications. Cauwenbergh G Drugs Exp Clin Res; 1986; 12(5):419-27. PubMed ID: 3522162 [TBL] [Abstract][Full Text] [Related]
11. Antifungal prophylaxis in immunocompromised hosts. Reents S; Goodwin SD; Singh V Ann Pharmacother; 1993 Jan; 27(1):53-60. PubMed ID: 8431623 [TBL] [Abstract][Full Text] [Related]
12. Oral ketoconazole and amphotericin B for the prevention of yeast colonization in patients with acute leukaemia. Donnelly JP; Starke ID; Galton DA; Catovsky D; Goldman JM; Darrell JH J Hosp Infect; 1984 Mar; 5(1):83-91. PubMed ID: 6202753 [TBL] [Abstract][Full Text] [Related]
13. Nystatin prophylaxis and treatment in severely immunodepressed patients. Gøtzsche PC; Johansen HK Cochrane Database Syst Rev; 2002; (4):CD002033. PubMed ID: 12519566 [TBL] [Abstract][Full Text] [Related]
14. Antifungal prophylaxis during neutropenia or allogeneic bone marrow transplantation: what is the state of the art? Ad HOC Working Group. Denning DW; Donnelly JP; Hellreigel KP; Ito J; Martino P; van't Wout JW Chemotherapy; 1992; 38 Suppl 1():43-9. PubMed ID: 1611930 [TBL] [Abstract][Full Text] [Related]
15. Comparative trial of ketoconazole and nystatin for prevention of fungal infection in neutropenic patients treated in a protective environment. Shepp DH; Klosterman A; Siegel MS; Meyers JD J Infect Dis; 1985 Dec; 152(6):1257-63. PubMed ID: 3905986 [TBL] [Abstract][Full Text] [Related]
16. Oral prophylaxis with miconazole or ketoconazole of invasive fungal disease in neutropenic cancer patients. Meunier-Carpentier F; Cruciani M; Klastersky J Eur J Cancer Clin Oncol; 1983 Jan; 19(1):43-8. PubMed ID: 6303794 [TBL] [Abstract][Full Text] [Related]
17. The outlook for antifungal prophylaxis in the compromised host. Young LS J Antimicrob Chemother; 1982 May; 9(5):338-40. PubMed ID: 6284692 [No Abstract] [Full Text] [Related]
18. [Prophylaxis against mycoses in neutropenic patients]. Arning M; Aul C Mycoses; 1994; 37 Suppl 2():70-6. PubMed ID: 7541892 [TBL] [Abstract][Full Text] [Related]
19. Therapy of fungal infections. Drutz DJ Bull N Y Acad Med; 1982 Nov; 58(8):721-32. PubMed ID: 6301590 [No Abstract] [Full Text] [Related]
20. Efficacy of ketoconazole v nystatin in prevention of fungal infections in neutropenic patients. Jones PG; Kauffman CA; McAuliffe LS; Liepman MK; Bergman AG Arch Intern Med; 1984 Mar; 144(3):549-51. PubMed ID: 6322710 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]